Long-acting synthetic oxytocin receptor agonist with functional Gq selectivity
A 1-deamino-1-monocarba analog of oxytocin developed by Ferring Pharmaceuticals as a heat-stable uterotonic for the prevention of postpartum hemorrhage, distinguished from native oxytocin by enzymatic resistance, prolonged duration of action, functional selectivity at the Gq signaling pathway, and investigational application in Prader-Willi syndrome hyperphagia.
Abstract
Carbetocin (1-deamino-1-monocarba-(2-O-methyltyrosine)-oxytocin; CAS 37025-55-1; molecular formula C45H69N11O12S; molecular weight 988.16) is a synthetic long-acting analog of the neurohypophysial peptide oxytocin, developed for the prevention of uterine atony and postpartum hemorrhage following cesarean and vaginal delivery. The compound incorporates two critical structural modifications relative to native oxytocin: replacement of the disulfide bridge with a thioether (monocarba) linkage that confers resistance to disulfide reductases, and deamination of the N-terminal cysteine residue that eliminates aminopeptidase-mediated degradation. Carbetocin acts as a selective agonist at the oxytocin receptor (OXTR), a class A G protein-coupled receptor expressed on myometrial smooth muscle, myoepithelial cells of the mammary gland, and neuronal populations in the hypothalamus, amygdala, and brainstem. Molecular pharmacology studies have characterized carbetocin as a functionally selective (biased) Gq agonist: it activates the Gq/phospholipase C/inositol trisphosphate signaling cascade with partial agonist efficacy while inducing receptor internalization through a beta-arrestin-independent pathway that prevents receptor recycling to the plasma membrane [3]. This functional selectivity profile distinguishes carbetocin from native oxytocin (which recruits both Gq and beta-arrestin pathways) and from vasopressin V1a/V1b receptors at which carbetocin shows negligible agonist activity. The compound was first approved in 1997 (Duratocin, Pabal; Ferring Pharmaceuticals) for prevention of uterine atony following cesarean delivery and is now registered in more than 80 countries. Pharmacokinetics after intravenous administration show biphasic elimination with a terminal half-life of approximately 33 minutes; intramuscular administration produces a terminal half-life of approximately 55 minutes with bioavailability exceeding 80 percent [7]. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.